Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluation

View Full Paper

Ask AI

Bookmark

Authors

Discussion

Key points are not available for this paper at this time.

Stevenson et al. (2016) studied this question.

View Full Paper

Ask AI

Bookmark